Drugs / donor-derived CIK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03821519 | Jan 2019 → May 2022 | hematopoietic and lymphoid cell neoplasm | A.O. Ospedale Papa Giovanni XXIII | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | donor-derived CIK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03821519 ↗ |
| Modality | Cell therapy | “CIK are a product of advanced cell therapy (Advanced Therapeutic Medicinal Product, ATMP) for somatic cell therapy” NCT03821519 ↗ |